DE3008082C2 - - Google Patents

Info

Publication number
DE3008082C2
DE3008082C2 DE3008082A DE3008082A DE3008082C2 DE 3008082 C2 DE3008082 C2 DE 3008082C2 DE 3008082 A DE3008082 A DE 3008082A DE 3008082 A DE3008082 A DE 3008082A DE 3008082 C2 DE3008082 C2 DE 3008082C2
Authority
DE
Germany
Prior art keywords
solution
phospholipid
injections
dispersion
lysophospholipid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired
Application number
DE3008082A
Other languages
German (de)
English (en)
Other versions
DE3008082A1 (de
Inventor
Yutaka Kodama
Kaoru Oyama
Ryusaku Shimizu
Masao Nakabayashi
Yoshifumi Nakashima
Takashi Sano
Masaaki Shibata
Kiyoshi Goden
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Toyama Chemical Co Ltd
Original Assignee
Toyama Chemical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from JP2460079A external-priority patent/JPS55118419A/ja
Priority claimed from JP11726279A external-priority patent/JPS5840929B2/ja
Application filed by Toyama Chemical Co Ltd filed Critical Toyama Chemical Co Ltd
Publication of DE3008082A1 publication Critical patent/DE3008082A1/de
Application granted granted Critical
Publication of DE3008082C2 publication Critical patent/DE3008082C2/de
Granted legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/683—Diesters of a phosphorus acid with two hydroxy compounds, e.g. phosphatidylinositols
    • A61K31/685—Diesters of a phosphorus acid with two hydroxy compounds, e.g. phosphatidylinositols one of the hydroxy compounds having nitrogen atoms, e.g. phosphatidylserine, lecithin

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
DE19803008082 1979-03-05 1980-03-03 Carcinostatisches und die immunreaktion stimulierendes mittel, enthaltend lysophospholipid und phospholipid, und verfahren zur herstellung desselben Granted DE3008082A1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2460079A JPS55118419A (en) 1979-03-05 1979-03-05 Antihemolytic composition consisting of fat emulsion and immunizator and carcinostatic agent containing the same
JP11726279A JPS5840929B2 (ja) 1979-09-14 1979-09-14 リゾレシチンおよびリン脂質を含有する制癌剤およびその製造法

Publications (2)

Publication Number Publication Date
DE3008082A1 DE3008082A1 (de) 1980-09-18
DE3008082C2 true DE3008082C2 (US06252093-20010626-C00008.png) 1988-02-11

Family

ID=26362150

Family Applications (1)

Application Number Title Priority Date Filing Date
DE19803008082 Granted DE3008082A1 (de) 1979-03-05 1980-03-03 Carcinostatisches und die immunreaktion stimulierendes mittel, enthaltend lysophospholipid und phospholipid, und verfahren zur herstellung desselben

Country Status (8)

Country Link
US (1) US4372949A (US06252093-20010626-C00008.png)
CA (1) CA1145260A (US06252093-20010626-C00008.png)
DE (1) DE3008082A1 (US06252093-20010626-C00008.png)
FR (1) FR2450608A1 (US06252093-20010626-C00008.png)
GB (1) GB2046092B (US06252093-20010626-C00008.png)
IT (1) IT1145357B (US06252093-20010626-C00008.png)
NL (1) NL8001292A (US06252093-20010626-C00008.png)
SE (1) SE459228B (US06252093-20010626-C00008.png)

Families Citing this family (94)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3127503A1 (de) * 1981-07-11 1983-02-17 Boehringer Mannheim Gmbh, 6800 Mannheim Neue phospholipide, verfahren zu deren herstellung und diese verbindungen enthaltende arzneimittel
IL63734A (en) * 1981-09-04 1985-07-31 Yeda Res & Dev Lipid fraction,its preparation and pharmaceutical compositions containing same
US4578391A (en) * 1982-01-20 1986-03-25 Yamanouchi Pharmaceutical Co., Ltd. Oily compositions of antitumor drugs
US4452747A (en) * 1982-03-22 1984-06-05 Klaus Gersonde Method of and arrangement for producing lipid vesicles
US5189017A (en) * 1982-07-23 1993-02-23 Ciba-Geigy Corporation Use of sugar derivatives for the prophylaxis and treatment of virus infections
US5334583A (en) * 1982-07-23 1994-08-02 Ciba-Geigy Corp. Use of sugar derivatives for the prophylaxis and treatment of virus infections
US5059591B1 (en) * 1983-05-26 2000-04-25 Liposome Co Inc Drug preparations of reduced toxicity
CA1237670A (en) * 1983-05-26 1988-06-07 Andrew S. Janoff Drug preparations of reduced toxicity
US4649155A (en) * 1983-07-22 1987-03-10 Hoffmann-La Roche Inc. Injectable solutions
JPS6045518A (ja) * 1983-08-22 1985-03-12 Takeda Chem Ind Ltd 抗シヨツク剤
US4873088A (en) * 1983-09-06 1989-10-10 Liposome Technology, Inc. Liposome drug delivery method and composition
JPS6081193A (ja) * 1983-10-11 1985-05-09 Takeda Chem Ind Ltd リン脂質
JPS60208910A (ja) * 1984-03-31 1985-10-21 Green Cross Corp:The 水難溶性薬物・リン脂質複合体の製造方法
PT78628B (en) * 1984-05-02 1986-06-18 Liposome Co Inc Pharmaceutical composition with reduced toxicity
DE3421468A1 (de) * 1984-06-08 1985-12-19 Dr. Rentschler Arzneimittel Gmbh & Co, 7958 Laupheim Lipidnanopellets als traegersystem fuer arzneimittel zur peroralen anwendung
DE3572491D1 (en) * 1984-07-25 1989-09-28 Ciba Geigy Ag Phosphatidyl compounds, process for their preparation and their use
US5736155A (en) * 1984-08-08 1998-04-07 The Liposome Company, Inc. Encapsulation of antineoplastic agents in liposomes
US5077056A (en) * 1984-08-08 1991-12-31 The Liposome Company, Inc. Encapsulation of antineoplastic agents in liposomes
US4921706A (en) * 1984-11-20 1990-05-01 Massachusetts Institute Of Technology Unilamellar lipid vesicles and method for their formation
US4622188A (en) * 1984-12-21 1986-11-11 E. I. Du Pont De Nemours And Company Method for manufacturing liposomes
US4737276A (en) * 1984-12-21 1988-04-12 E. I. Du Pont De Nemours And Company Apparatus for manufacturing liposomes
US5409704A (en) * 1985-06-26 1995-04-25 The Liposome Company, Inc. Liposomes comprising aminoglycoside phosphates and methods of production and use
US4916249A (en) * 1985-07-03 1990-04-10 Hans Brachwitz Glycero-3(2)-phospho-L-serine derivatives and salts thereof
US4857514A (en) * 1985-09-17 1989-08-15 Yeda Research And Development Company, Ltd. Virus inactivation
DE3683487D1 (de) * 1985-10-21 1992-02-27 Liposome Co Inc In situ-herstellung und verabreichung von liposomen.
US4923854A (en) * 1986-01-22 1990-05-08 The Liposome Company, Inc. Solubilization of hydrophobic materials using lysophospholipid
US4873322A (en) * 1986-01-24 1989-10-10 Ciba-Geigy Corporation Saccharide derivatives and processes for their manufacture
US4737323A (en) * 1986-02-13 1988-04-12 Liposome Technology, Inc. Liposome extrusion method
US4971801A (en) * 1986-06-09 1990-11-20 Cell Technology, Inc. Biologic response modifier
US5009956A (en) * 1987-02-24 1991-04-23 Univ Minnesota Phospholipase A2-resistant liposomes
MX9203808A (es) * 1987-03-05 1992-07-01 Liposome Co Inc Formulaciones de alto contenido de medicamento: lipido, de agentes liposomicos-antineoplasticos.
US6406713B1 (en) 1987-03-05 2002-06-18 The Liposome Company, Inc. Methods of preparing low-toxicity drug-lipid complexes
US5616334A (en) * 1987-03-05 1997-04-01 The Liposome Company, Inc. Low toxicity drug-lipid systems
WO1988007850A1 (en) * 1987-04-16 1988-10-20 The Liposome Company, Inc. Liposome continuous size reduction method and apparatus
US5145844A (en) * 1987-07-23 1992-09-08 Hoechst-Roussel Pharmaceuticals Incorporated Methods of using hydroxy-, alkoxy- and benzyloxy-substituted phospholipids to treat phospholipase A2 -mediated conditions and to alleviate pain
US5030733A (en) * 1987-07-23 1991-07-09 Hoechst-Roussel Pharmaceticals Incorporated Hydroxy-, alkoxy- and benzyloxy-substituted phospholipids
US4978332A (en) * 1987-09-28 1990-12-18 Matrix Pharmaceutical, Inc. Treatments employing vasoconstrictive substances in combination with cytotoxic agents for introduction into cellular lesion areas
US5185334A (en) * 1989-07-31 1993-02-09 Schering Corporation 2,2-disubstituted glycerol and glycerol-like compounds, compositions and methods of use
US4888328A (en) * 1988-03-10 1989-12-19 Hoeschst-Roussel Incorporated Alkoxycarbonylalkylphospholipids and alkylaminocarbonylalkylphospholipids
US5036152A (en) * 1988-03-10 1991-07-30 Hoechst-Roussel Pharmaceuticals Incorporated Alkoxycarbonylalkylphospholipids and alkylaminocarbonylalkylphospholipids
US5230900A (en) * 1988-07-01 1993-07-27 The Biomembrane Institute Antibody-mediated and ligand-mediated targeting of differentiation-inducers to tumor cells
EP0370457B1 (en) * 1988-11-23 1992-12-16 Abbott Laboratories Lipid emulsion for treating aids
DE3906952A1 (de) * 1989-03-04 1990-09-06 Boehringer Mannheim Gmbh (3-(c(pfeil abwaerts)1(pfeil abwaerts)(pfeil abwaerts)6(pfeil abwaerts)-c(pfeil abwaerts)1(pfeil abwaerts)(pfeil abwaerts)8(pfeil abwaerts))alkansulfinyl- und sulfonyl-2-methoxymethyl-propyl)-(2-trimethylammonio-ethyl) phosphate, verfahren zu deren herstellung diese verbindungen enthaltende arzneimittel
US5100662A (en) * 1989-08-23 1992-03-31 The Liposome Company, Inc. Steroidal liposomes exhibiting enhanced stability
DK0555229T3 (da) * 1990-07-31 1996-08-19 Liposome Co Inc Akkumulation af aminosyrer og peptider i liposomer
WO1992008448A1 (en) * 1990-11-09 1992-05-29 Cell Technology, Inc. Method for preventing drug-induced or radiation myelosuppression
US5620703A (en) * 1991-10-11 1997-04-15 Max-Delbruck-Centrum Fur Molekulare Medizin Stimulating hematopoietic activity with carboplatin or lobaplatin
US5817646A (en) * 1991-11-15 1998-10-06 Laboratoires Inocosm Polar lipid composition of plant origin
IT1255476B (it) * 1992-07-30 1995-11-02 Glicerofosfoderivati farmacologicamente attivi
CA2171281C (en) 1993-09-09 1998-12-29 Romeo Rang Immunomodulating compositions from bile
US6551623B1 (en) 1993-09-09 2003-04-22 Lorus Therapeutics Inc. Immunomodulating compositions from bile
US5707978A (en) * 1994-11-22 1998-01-13 Clarion Pharmaceuticals Inc. Heteroaryl-substituted deoxy glycero-phosphoethanolamines
CA2215339C (en) 1995-03-16 1999-01-19 Imutec Pharma Inc. Immunomodulating compositions from bile for the treatment of immune system disorders
US5990077A (en) 1995-04-14 1999-11-23 1149336 Ontario Inc. Glucagon-like peptide-2 and its therapeutic use
US6184201B1 (en) 1995-04-14 2001-02-06 Nps Allelix Corp. Intestinotrophic glucagon-like peptide-2 analogs
US5834428A (en) * 1995-04-14 1998-11-10 1149336 Ontario Inc. Glucagon-like peptide-2 and its therapeutic use
US5665714A (en) * 1995-12-07 1997-09-09 Clarion Pharmaceuticals Inc. N-substituted glycerophosphoethanolamines
US5703062A (en) * 1995-12-07 1997-12-30 Clarion Pharmaceuticals Inc. N-het-substituted glycerophosphoethanolamines
US5730157A (en) * 1995-12-07 1998-03-24 Clarion Pharmaceuticals Inc. Method for treating viral infection
JP4148994B2 (ja) 1996-04-12 2008-09-10 １１４９３３６ オンタリオ インコーポレイテッド グルカゴン様ペプチド―２アナログ
US20040101569A1 (en) * 1996-05-16 2004-05-27 Lorus Therapeutics Inc. Immunomodulating compositions from bile
US6111081A (en) * 1996-05-31 2000-08-29 Baylor College Of Medicine Lactoferrin variants and uses thereof
US5932242A (en) * 1996-10-15 1999-08-03 The Liposome Company, Inc. Ether lipid-containing pharmaceutical compositions and therapeutic uses thereof
US6037125A (en) * 1996-11-05 2000-03-14 Lexicon Genetics Incorporated Disruption of the mammalian RAD51 protein and disruption of proteins that associate with mammalian RAD51 for hindering cell proliferation and/or viability of proliferating cells
US5827836A (en) * 1996-11-15 1998-10-27 Clarion Pharmaceuticals Inc. Retinoid glycerol phospholipid conjugates
CA2236519C (en) 1997-05-02 2011-09-13 1149336 Ontario Inc. Methods of enhancing functioning of the large intestine
GB9906695D0 (en) * 1999-03-24 1999-05-19 Secr Defence Vaccine composition
US20020001614A1 (en) * 2000-02-10 2002-01-03 Kent Jorgensen Lipid-based drug delivery systems containing phospholipase A2 degradable lipid derivatives and the therapeutic uses thereof
CA2477982A1 (en) * 2002-03-05 2003-09-18 Transave, Inc. Methods for entrapment of bioactive agent in a liposome or lipid complex
US7879351B2 (en) * 2002-10-29 2011-02-01 Transave, Inc. High delivery rates for lipid based drug formulations, and methods of treatment thereof
US7718189B2 (en) 2002-10-29 2010-05-18 Transave, Inc. Sustained release of antiinfectives
EP3427742B1 (en) * 2002-10-29 2020-08-12 Insmed Incorporated Liposomes comprising an aminoglycoside for the treatment of pulmonary infections
US20060078560A1 (en) * 2003-06-23 2006-04-13 Neopharm, Inc. Method of inducing apoptosis and inhibiting cardiolipin synthesis
JP2008516899A (ja) * 2004-10-15 2008-05-22 ビオファーマコペ デジン アンテルナショナル インク． 癌治療のための植物抽出物から成る方法および成分
EP1745788A1 (de) * 2005-07-22 2007-01-24 KTB Tumorforschungsgesellschaft mbH Acylglycerophospholipide zur Behandlung von Krebs und Tumorkachexie
US8226975B2 (en) 2005-12-08 2012-07-24 Insmed Incorporated Lipid-based compositions of antiinfectives for treating pulmonary infections and methods of use thereof
WO2008137717A1 (en) 2007-05-04 2008-11-13 Transave, Inc. Compositions of multicationic drugs for reducing interactions with polyanionic biomolecules and methods and uses thereof
US9119783B2 (en) 2007-05-07 2015-09-01 Insmed Incorporated Method of treating pulmonary disorders with liposomal amikacin formulations
US9114081B2 (en) 2007-05-07 2015-08-25 Insmed Incorporated Methods of treating pulmonary disorders with liposomal amikacin formulations
US9333214B2 (en) 2007-05-07 2016-05-10 Insmed Incorporated Method for treating pulmonary disorders with liposomal amikacin formulations
US7960336B2 (en) 2007-08-03 2011-06-14 Pharmain Corporation Composition for long-acting peptide analogs
CN101358609A (zh) * 2007-08-03 2009-02-04 富准精密工业(深圳)有限公司 风扇转子
EP2555791B1 (en) 2010-04-09 2017-11-01 Sinai Health System Methods for treating disorders of the gastrointestinal tract using a glp-1 agonist
JP6402097B2 (ja) 2012-05-21 2018-10-10 インスメッド インコーポレイテッド 肺感染症を処置するためのシステム
MX2015006681A (es) 2012-11-29 2016-04-06 Insmed Inc Formulaciones de vancomicina estabilizadas.
KR101951933B1 (ko) * 2013-03-12 2019-02-25 주식회사 아리바이오 라이소포스파티딜콜린 또는 이의 유도체를 포함하는 지질나노물질 및 이의 제조방법
EP3019188B1 (en) 2013-07-08 2022-03-09 The University of Utah Research Foundation A peptide and the use thereof in the treatment of inflammatory disorders
EP3135297A4 (en) * 2014-04-04 2018-02-07 Osaka University Drug delivery promoter containing substance for activating lysophospholipid receptors
SI3466432T1 (sl) 2014-05-15 2020-11-30 Insmed Incorporated Postopek zdravljenja pljučnih netuberkuloznih mikobakterijskih okužb
AU2016329670B2 (en) * 2015-09-29 2019-12-12 Osaka University Leukocyte infiltration promoting agent and antitumor immunostimulatory agent
CZ308596B6 (cs) * 2017-04-03 2020-12-23 Ústav molekulární genetiky AV ČR, v. v. i. Deriváty fosfolipidů a jejich použití jako léčiva
WO2018204918A1 (en) 2017-05-05 2018-11-08 Ardelyx, Inc. Treatment of hepatic disorders
JP7460534B2 (ja) 2018-03-30 2024-04-02 インスメッド インコーポレイテッド リポソーム医薬品の連続製造方法
EP3895709A1 (de) 2020-04-17 2021-10-20 Andreas Hettich GmbH & Co. KG Phospholipide und phospholipid-metaboliten zur behandlung von viralen und bakteriellen lungenentzündungen und sepsis

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2009341C3 (de) * 1970-02-27 1979-06-21 Max-Planck-Gesellschaft Zur Foerderung Der Wissenschaften E.V., 3400 Goettingen 3-Octadecyloxy-propanol-(l)-phosphorsäure-monocholinester und Verfahren zu dessen Herstellung
US4119714A (en) * 1970-02-27 1978-10-10 Max-Planck-Gesellschaft Zur Forderung Der Wissenschaften E. V. Glycerin-alkylether-(1)-phosphoric acid-(3)-monocholine esters as enhancers of the natural resistance of the mammalian organism against non-carcinogenic pathogens
DE2009342C3 (de) * 1970-02-27 1980-12-18 Max-Planck-Gesellschaft Zur Foerderung Der Wissenschaften E.V., 3400 Goettingen Verwendung von Glycerin-alkyläther-(l)-phosphorsäure-(3)-monocholinestern
DE2009343C3 (de) * 1970-02-27 1980-10-23 Max-Planck-Gesellschaft Zur Foerderung Der Wissenschaften E.V., 3400 Goettingen Verwendung von Lysolecithinen als immunologische Adjuvantien
FR2287901A1 (fr) 1974-10-14 1976-05-14 Pasteur Institut Medicament immunostimulant contenant un derive d'ose ou de polyose phosphoryle
JPS5186117A (en) * 1975-01-27 1976-07-28 Tanabe Seiyaku Co Johoseibiryushiseizainoseiho
DE2619686C2 (de) 1976-05-04 1986-08-07 Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V., 3400 Göttingen Verwendung eines Lysolecithins zur Tumorbehandlung

Also Published As

Publication number Publication date
DE3008082A1 (de) 1980-09-18
CA1145260A (en) 1983-04-26
IT1145357B (it) 1986-11-05
IT8048066A0 (it) 1980-03-04
SE459228B (sv) 1989-06-19
SE8001685L (sv) 1980-10-20
US4372949A (en) 1983-02-08
FR2450608B1 (US06252093-20010626-C00008.png) 1984-12-21
GB2046092A (en) 1980-11-12
GB2046092B (en) 1983-11-02
NL8001292A (nl) 1980-09-09
FR2450608A1 (fr) 1980-10-03

Similar Documents

Publication Publication Date Title
DE3008082C2 (US06252093-20010626-C00008.png)
DE3016976A1 (de) Liposom mit einem gehalt an einer aktiven substanz und verfahren zu dessen herstellung
EP0711557A1 (de) Pharmazeutische Formulierungsgrundlage
DE3021006C2 (de) Oberflächenaktives Material und dieses Material enthaltendes pharmazeutisches Mittel gegen Hyalin-Membran-Erkrankung
DE69534002T2 (de) Verwendung von Phosphatidylserinen zur Herstellung eines Arzneimittels zur Verbesserung der Gehirntätigkeit
DE3512926A1 (de) Verbesserung in oder bezueglich der therapie mit interleukin
CH681153A5 (de) Neue sterolester- und sterolphosphorverbindungen.
DE3852409T2 (de) Aus Phospholipiden bestehende Darreichungsform für wasserunlösliche Wirksubstanzen.
DE3515335C2 (de) Arzneizubereitung enthaltend Dihydropyridine und Verfahren zu ihrer Herstellung
EP0461559B1 (de) Wirkstofffreie Liposomen zur Behandlung von Atherosklerose
EP0451791A2 (de) Langwirksame Liposomenpräparate von Peptidarzneistoffen und Verfahren zu ihrer Herstellung
DE3786304T2 (de) Immunostimulierende Arzneimittel.
EP0630231B1 (de) Liposomen mit negativer überschussladung
EP1239862B1 (de) Pharmazeutische zubereitung enthaltend zytostatika und elektronenakzeptoren zur behandlung von krebs
EP0488142B1 (de) Verfahren zur Verkapselung fester oder flüssiger, lipophiler Wirkstoffe zu diesen Wirkstoff enthaltenden Phospholipid-Liposomen sowie Arzneimittel diese Liposomen enthaltend
DE3872875T2 (de) Verfahren zur herstellung von liposomen.
EP0406732B1 (de) Niedrig-viskose, hochkonzentrierte Surfactant-Suspension
EP0470437B1 (de) Wässriges Liposomensystem
EP0535567B1 (de) Flüchtige Inhalationsnarkotika enthaltende Liposomen, ihre Herstellung und Verwendung
DE60127140T2 (de) Amphotericin b enthaltende strukturierte emulsion
DE3309076C2 (de) Liposome und Verfahren zu ihrer Herstellung
DE2546001A1 (de) Immunostimulierende phospholipide und sie enthaltende arzneimittel
DE3042975A1 (de) Mikrodispersion mit einem wirkstoff und/oder einem reagens in salzform als disperser phase
DE4308121A1 (de) Wäßriges Liposomensystem sowie Verfahren zur Herstellung eines derartigen Liposomensystems
DE10015814A1 (de) Arzneimittel zur Stimulierung der Leukopoese, zur Behandlung von Tumor- und Protozoenerkrankungen und Verfahren zu seiner Herstellung

Legal Events

Date Code Title Description
8110 Request for examination paragraph 44
8125 Change of the main classification

Ipc: A61K 31/685

D2 Grant after examination
8364 No opposition during term of opposition
8339 Ceased/non-payment of the annual fee